2. Signaling Pathways
  3. Immunology/Inflammation
  4. IFNAR

IFNAR

Interferon-α/β receptor; Interferon-alpha/beta receptor

IFNAR

Related Products

PDF 0.27 MB

The interferon-α/β receptor (IFNAR) is composed of two subunits, IFNAR1 and IFNAR2, encoding transmembrane polypeptides. Type-I IFNs, interferon α (IFN-α) and interferon β (IFN-β), act through a shared receptor complex, IFNAR. Binding of type-I IFN to IFNAR1 will robustly activate Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Aberrant activation of the type-I IFN response results in a spectrum of disorders called interferonopathies.

Type-I IFN response occurs when IFN-α/β binds to their receptor complex, IFNAR. The ligand-receptor complex is phosphorylated, presumably by pre-associated Janus activated kinases (JAKs) namely tyrosine kinase 2 (TYK2) on IFNAR1 and JAK1 on IFNAR2. The phosphorylated receptors are docking sites for signal transducers and activators of transcription (STAT) factors that dimerise and translocate to the nucleus. STATs 1, 2, 3, 4, and 5 are activated by type-I IFNs in many cell types. Other kinases (e.g., mitogen-activated protein kinases) and transcription factors (e.g., nuclear factor-κB) can also be activated in response to type-I IFNs. Multiple pathways and IFN-regulated genes are activated by IFNs, many of which remain unknown.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-176426
    Subquinocin
    		Activator
    Subquinocin is a CYLD inhibitor that inhibits USP family deubiquitinases (DUBs). Subquinocin enhances the activation of NF-κB and IFN pathways by inhibiting CYLD. Subquinocin promotes RIG-I-mediated activation of IRF3 and/or IRF7 in the interferon pathway.
    Subquinocin
  • HY-W011890A
    Cridanimod sodium
    		Activator
    Cridanimod sodium is an antiviral agent that induces interferon production in mice. Cridanimod can be utilized in antiviral research.
    Cridanimod sodium
  • HY-N10341
    Centaureidin
    		Activator
    Centaureidin is an orally active IFN-promoter that can be isolated from Bidens pilosa with an EC50 of 0.9 μg/mL. Centaureidin activates the Rho signal pathway, leading to actin and tubulin disassembly, and resulting in dendrite retraction and stress fiber formation in melanocytes. Centaureidin shows high tumor cell growth inhibitory activities. Centaureidin significantly inhibits paw edema in mice[1][2][3][4][5].
    Centaureidin
  • HY-175195
    Adenosine receptor antagonist 6
    		Activator
    Adenosine receptor antagonist 6, a (S)-enantiomer compound, is an orally active and selective A2A adenosine receptor (A2AAR) antagonist. Adenosine receptor antagonist 6 binds to the A2A adenosine receptor with a Ki of 19.18 nM. Adenosine receptor antagonist 6 inhibits 5’-N-ethylcarboxamide adenosine (NECA) (HY-103173)-mediated cAMP production (IC50 = 0.089 μM) and immunosuppression, while promoting IL-2 and IFN-γ secretion. Adenosine receptor antagonist 6 abolishes the immunosuppressive effects of adenosine on T-cell activation and cytokine release. Adenosine receptor antagonist 6 inhibits tumor growth in a CT26/MC38 xenograft model. Adenosine receptor antagonist 6 can be used for the study of colon cancer.
    Adenosine receptor antagonist 6
  • HY-117287A
    Deucravacitinib hydrochloride
    		Inhibitor
    Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition.
    Deucravacitinib hydrochloride
  • HY-P10710
    BMP-4
    		Inhibitor
    BMP-4 is a penetrating heparin-binding peptide with anti-inflammatory and anti-chondrogenic functions. In murine chondrocytes and macrophages, BMP-4 regulates the iNOS-IFN-IL6 signaling pathway to inhibit the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6 in a dose-dependent manner, effectively suppressing inflammation and alleviating various arthritis symptoms.
    BMP-4
  • HY-P991251
    QX006N
    		Inhibitor
    QX006N is a humanized monoclonal antibody inhibitor targeting human interferon α/β receptor 1 (IFNAR1). QX006N is promising for research of systemic lupus erythematosus (SLE) and other IFNAR1-related autoimmune diseases.
    QX006N
  • HY-119347R
    Cirsilineol (Standard)
    		Inhibitor
    Cirsilineol (Standard) is the analytical standard of Cirsilineol. This product is intended for research and analytical applications. Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4+ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice.
    Cirsilineol (Standard)
  • HY-173399
    hSTING activator-1
    		Inducer
    hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
    hSTING activator-1
  • HY-113271
    5-Androstenetriol
    		Activator
    5-Androstenetriol is a systemic radiation protector that can boost the host's immunity, leading to increased resistance to infections. 5-Androstenetriol can raise levels of IL-2, IL-3, and IFN, while countering the immunosuppressive effects of Hydrocortisone (HY-N0583).
    5-Androstenetriol
  • HY-168971
    Paeoniflorin-6′-O-benzene sulfonate
    		Antagonist
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model.
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-P991408
    DLX-105
    		Inhibitor
    DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research.
    DLX-105
  • HY-170331
    IFNα-IN-1
    		Inhibitor
    IFNα-IN-1 (AJ2-18) is a IFNα inhibitor that inhibits IFN-α production. IFNα-IN-1 can be used for research of inflammation.
    IFNα-IN-1
  • HY-106359
    Delmitide
    		Inhibitor
    Delmitide (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide can be used for the research of ulcerative colitis.
    Delmitide
  • HY-173180
    5-LOX-IN-8
    		Inhibitor
    5-LOX-IN-8 is a 5-LOX inhibitor with anti-inflammatory activity. 5-LOX-IN-8 suppresses IL-6, IL-1β, TNF-α and IFN-γ in macrophages and reduces IL-8 secretion in SW480 cells. 5-LOX-IN-8 reduces disease activity in a DSS colitis model. 5-LOX-IN-8 can be used for research of inflammatory bowel disease (IBD).
    5-LOX-IN-8
  • HY-175210
    STING-IN-16
    		Inhibitor
    STING-IN-16 is a STING inhibitor with IC50 values of 44 nM (human) and 32 nM (mice) for cellular STING inhibition. STING-IN-16 effectively inhibits the activation of the STING axis in both human and murine cells. STING-IN-16 can restore renal mitochondrial function, suppress reactive oxygen species (ROS) production, and reduce cell apoptosis. STING-IN-16 shows robust anti-inflammatory efiicacy in vivo. STING-IN-16 can be used for the study of autoimmune and autoinflammatory diseases.
    STING-IN-16
  • HY-120049
    TAK-603
    		Inhibitor
    TAK-603 is a potent and orally active antirheumatic agent. TAK-603 inhibits Thl-type cytokine production. TAK-603 has the potential for the research of adjuvant arthritis.
    TAK-603
  • HY-19943
    TLC388
    		Inducer
    TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.
    TLC388
  • HY-P991436
    DF6002
    		Activator
    DF6002 (BMS-986415) is a human monoclonal antibody (mAb) targeting IL-12. DF6002 increases IFN-γ levels. DF6002 can be used in solid tumors research.
    DF6002
  • HY-N15169
    BG-136
    		Activator
    BG-136 is an innate immune stimulant isolated from Durvillaea Antarctica that can simultaneously stimulate the activation of both innate and adaptive immune cells in the tumor microenvironment (TME), exerting a broad-spectrum antitumor effect.
    BG-136
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity